Redd&Whyte Appoints New Director of Business Development
News Aug 23, 2012
The appointment is one of a series of new hires, amid strategic restructuring within Redd&Whyte.
Rob Harkness brings specialist technical understanding of software and robotics, in addition to an impressive track record in business development.
He joins Redd&Whyte from Process Analysis & Automation, Ltd (PAA), where he worked for 13 years, initially as a software programmer and project manager, before progressing to leading Business Development in 2010.
His PhD (University of Surrey) focused on novel scheduling software for biochemical assays.
Rob made a significant contribution to PAA’s success in becoming a major provider of laboratory automated solutions, and will now lead Redd&Whyte’s global Business Development team.
“This is a crucial time for our company,” said Roger Poole, Managing Director at Redd&Whyte. “We have been making significant changes on a number of levels over the past few months, and Rob’s appointment forms an important part of our new business strategy.”
“It also demonstrates our continued commitment to developing enabling technology for our customers, through our approach of open innovation,” Roger said.
Roger continued, “Our products, including the award-winning Preddator microplate dispenser, are all developed through close collaboration with our customers, to help solve their liquid handling challenges and overcome perceived barriers to research.”
Redd&Whyte is involved in developing a range of novel robotic instruments with the fluid handling capabilities that laboratory scientists need to actually achieve their research visions.
The company’s specialist areas include nano dispensing, high throughput screening and point of care (PoC) testing.
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
New Drug Class: Potential Therapeutics for Alzheimer’s Disease?News
One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018